DE1028743B - Process for the production of concentrated, durable aqueous solutions of furanochromones - Google Patents

Process for the production of concentrated, durable aqueous solutions of furanochromones

Info

Publication number
DE1028743B
DE1028743B DEU4381A DEU0004381A DE1028743B DE 1028743 B DE1028743 B DE 1028743B DE U4381 A DEU4381 A DE U4381A DE U0004381 A DEU0004381 A DE U0004381A DE 1028743 B DE1028743 B DE 1028743B
Authority
DE
Germany
Prior art keywords
solution
furanochromones
concentrated
methyl
aqueous solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEU4381A
Other languages
German (de)
Inventor
Dr Gerhard Kaellner
Dr Med Kurt Uhlenbroock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Upha Chem Pharm Praeparate G M
Original Assignee
Upha Chem Pharm Praeparate G M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upha Chem Pharm Praeparate G M filed Critical Upha Chem Pharm Praeparate G M
Priority to DEU4381A priority Critical patent/DE1028743B/en
Publication of DE1028743B publication Critical patent/DE1028743B/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Description

Beispiel 2 In 100 ccm einer 15°/oigen wäßrigen Natriumsalicylatlösung werden 5 g 2-Methyl-2-n-propyl-1,3-propandioldicarbamat und 5 g 2-Methyl-5. 8-dimethoxyfuranochromon, wie im Beispiel 1 beschrieben, zur Lösung gebracht. Die Lösung ist stabil und läßt sich in Ampullen abfüllen und sterilisieren. Ohne den Einsatz von 2-Methyl-2-n-propyl-l, 3-propandioldicarbamat gelingt es nicht, die im Beispiel angegebene Menge in 100 ccm der 15°/oigen Natriumsalicylatlösung stabil zu lösen. Example 2 In 100 cc of a 15% aqueous sodium salicylate solution 5 g of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate and 5 g of 2-methyl-5. 8-dimethoxyfuranochromone, as described in Example 1, for Solution brought. The solution is stable and leaves Fill in ampoules and sterilize. Without the use of 2-methyl-2-n-propyl-l, 3-propanediol dicarbamate does not succeed in the amount given in the example in 100 ccm of the 15% sodium salicylate solution to dissolve stably.

PATENTANSPRUCH Weitere Ausbitdung des Verfahrens des Patents 904 652 zur Herstellung von konzentrierten, haltbaren wäßrigen Lösungen von Furanochromonen unter Verwendung von Natriumsalicylat als Lösungsvermittler, dadurch gekennzeichnet, daß zusammen mit Natriumsalicylat 2-Methyl-2-npropyl-1, 3-propandioldicarhamat als Lösungsverbesserer verwendet wird. PATENT CLAIM Further elaboration of the process of patent 904 652 for the preparation of concentrated, long-lasting aqueous solutions of furanochromones using sodium salicylate as a solubilizer, characterized in that that together with sodium salicylate 2-methyl-2-n-propyl-1, 3-propanediol dicarhamate as Solution enhancer is used.

Claims (1)

Verfahren zur Herstellung konzentrierter, haltbarer wäßriger Lösungen von Furanochromonen Zusatz zum Patent 904 652 Das veröffentlichte Hauptpatent letrifft nach seinem Anspruch l ein NTerfahren zur Herstellung konzentrierter, haltbarer wäßriger Lösungen von Furanochromonen, wol) ei man als Lösungsvermittler cyclische Oxycarbonsäuren oder Oxysulfonsäuren bzw. deren wasserlösliche Salze verwendet.Process for the preparation of concentrated, stable aqueous solutions of furanochromones Addendum to Patent 904,652 The main published patent applies according to his claim l an NTerfahren for the production of concentrated, more durable aqueous solutions of furanochromones, wol) ei as solubilizers cyclic Oxycarboxylic acids or oxysulfonic acids or their water-soluble salts are used. In erster Linie werden dabei Salicylsäure und ihre wasserlöslichen Salze, insbesondere Natriumsalicylat verwendet. First and foremost, salicylic acid and its water-soluble ones Salts, especially sodium salicylate, are used. In weiterer Ausbildung der Erfindung des Hauptpatents wurde nun gefunden, daß man die lösungsverbessernde Wirkung des Natriumsalicylats noch w esentlich erhöhen kann, wenn man zusätzlich 2-Methyl-2-n-propyl-1, 3-propandioldicarbamat als zweiten Lösungsverbesserer verwendet. Es gelingt auf diese Weise, Lösungen höherer Konzentration an Furanochromonen bei Einhaltung pharmakologisch unwirksamer bzw. im Organismus nicht störender Mengen von NatriumsaHcylat zu erzielen. Es ist auf diese Weise leicht möglich, die Konzentration der Injektionslösung an Khellin bis auf 50 mg pro ccm gegenüber etwa 10 mg nach dem Hauptpatent zu steigern, ohne daß nachteilige Nebenwirkungen damit verbunden sind. In a further development of the invention of the main patent it has now been found that the solution-improving effect of sodium salicylate can be increased considerably can, if you also 2-methyl-2-n-propyl-1, 3-propanediol dicarbamate as the second Solution improvers used. In this way it is possible to find solutions of higher concentration on furanochromones if they are pharmacologically ineffective or in the organism to achieve non-interfering amounts of sodium acylate. It's easy that way possible, the concentration of the injection solution of khellin up to 50 mg per ccm compared to about 10 mg according to the main patent, without adverse side effects associated with it. B e i s p i e l 1 In 100 ccm einer 15°/oigen Losung von atriumsalicylat wird unter Wärmen ein Gemisch von 1 g 2-Methvl-2-n-propyl-1, 3-propandioldicarbamat und 3 g 2-Methyl-5, 8-dimethoxyfuranochromon eingetra-@ gen und unter Erwärmen und Rühren zur Lösung gebracht. Die erhaltene Lösung ist stabil. läßt sich in Ampullen füllen und sterilisieren. Ex. 1 in 100 cc of a 15% solution of atrium salicylate a mixture of 1 g of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate is added with warming and 3 g of 2-methyl-5, 8-dimethoxyfuranochromone entered and with heating and Stirring brought to solution. The solution obtained is stable. can be in ampoules fill and sterilize.
DEU4381A 1957-02-20 1957-02-20 Process for the production of concentrated, durable aqueous solutions of furanochromones Pending DE1028743B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEU4381A DE1028743B (en) 1957-02-20 1957-02-20 Process for the production of concentrated, durable aqueous solutions of furanochromones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEU4381A DE1028743B (en) 1957-02-20 1957-02-20 Process for the production of concentrated, durable aqueous solutions of furanochromones

Publications (1)

Publication Number Publication Date
DE1028743B true DE1028743B (en) 1958-04-24

Family

ID=7565523

Family Applications (1)

Application Number Title Priority Date Filing Date
DEU4381A Pending DE1028743B (en) 1957-02-20 1957-02-20 Process for the production of concentrated, durable aqueous solutions of furanochromones

Country Status (1)

Country Link
DE (1) DE1028743B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076328B (en) * 1958-11-17 1960-02-25 Thiemann Chem Pharm Fab Process for the production of stable aqueous khellin solutions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1076328B (en) * 1958-11-17 1960-02-25 Thiemann Chem Pharm Fab Process for the production of stable aqueous khellin solutions

Similar Documents

Publication Publication Date Title
DE1028743B (en) Process for the production of concentrated, durable aqueous solutions of furanochromones
DE690488C (en) Process for the production of concentrated aqueous caffeine solutions
DE540016C (en) Process for converting CC-disubstituted barbituric acids into durable injectable solutions
DE904652C (en) Process for the production of concentrated, durable aqueous solutions of furanochromones
DE529423C (en) Process for the production of concentrated aqueous solutions of tribromomethyl alcohol
DE932083C (en) Process for the production of stable aqueous injection solutions of 2-methyl-5, 8-dimethoxy-furanochromone
DE666266C (en) Process to increase the water solubility of azo compounds
DE1062390B (en) Process for increasing the solubility of 2-methyl-2-n-propyl-1,3-propane-diol dicarbamate
DE800413C (en) Process for the production of neutral solutions of polyalkylxanthines
DE574564C (en) Process for the preparation of salts of dibasic organic acids
DE812912C (en) Process for the preparation of a mixture of hexamethylene tetramine rhodanide and ammonium sulfate
DE936818C (en) Process for the production of aqueous solutions of drugs that are poorly soluble in water
DE929092C (en) Process for the production of polyamide solutions
DE951756C (en) Process for the production of concentrated, long-lasting aqueous solutions of furanochromones
DE558752C (en) Process for the production of neutral complex antimony salts
DE908857C (en) Process for the preparation of an easily soluble compound from theophylline and 3-aminomethylpyridine
DE951004C (en) Process for the preparation of hydrazones of cyanoacetic acid hydrazide with ketocarboxylic acids or their esters
DE881858C (en) Process for the preparation of solutions of sulfathiourea
DE937726C (en) Process for the stabilization of aqueous solutions of furanochromones
DE915851C (en) Process for the preparation of solutions containing tyrothricin and streptomycin or dihydrostreptomycin
DE424659C (en) Process for the preparation of methylaminoaceto-catechol dibenzyl ether
DE666789C (en) Process for the production of sulfur-containing heavy metal complex compounds
DE903624C (en) Process for the preparation of durable, injectable solutions of 1-phenyl-2, 3-dialkyl-4-dialkylamino-5-pyrazolones
DE1126069B (en) Process for the preparation of intravenous injectable, stable aqueous solutions of 2-AEthyl-pyridine-4-carbothionamide
DE405384C (en) Process for the preparation of dipolyoxyalkyl ethers of dithioalkylenes